Position
Renaissance Technologies in Cullinan Therapeutics, Inc.
Back to the book · All holders of CGEM
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $1.3M$14.21 → $18.21
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 631.7K | $6.54M | — | — | — | 0.0% |
| Q1 2026 | 324.1K | $4.61M | $14.21 | $1.25M | −$3.18M | 0.0% |
| Q2 2026 | 326.8K | $5.95M | $18.21 | $1.3M | $49.2K | 0.0% |